Evaxion announces 2025 milestones reflecting continued strong strategy execution
Evaxion Biotech A/S - American Depositary Share (EVAX)
Company Research
Source: GlobeNewswire
With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025The 2025 key milestones reflect all parts of Evaxion’s strategy for value realizationEvaxion expects to discuss the milestones at an investor event in the first quarter of 2025 COPENHAGEN, Denmark, December 9, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces its strategic milestones for 2025 after having now achieved almost all the milestones set for 2024. The 2025 milestones reflect Evaxion’s high activity level, broad pipeline and strong external interest in potential partnerships around both our AI-Immunology™ platform and pipeline assets. As such, the milestones underscore our continued anticipated strategic progress. “We have been very successful in executing our strategy and plans throughout 2024. This makes us excited and confident looking into 2025
Show less
Read more
Impact Snapshot
Event Time:
EVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVAX alerts
High impacting Evaxion Biotech A/S - American Depositary Share news events
Weekly update
A roundup of the hottest topics
EVAX
News
- Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity [Yahoo! Finance]Yahoo! Finance
- Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equityGlobeNewswire
- Evaxion establishes new AI-derived precision cancer vaccine concept [Yahoo! Finance]Yahoo! Finance
- Evaxion establishes new AI-derived precision cancer vaccine conceptGlobeNewswire
- Evaxion announces 2025 milestones reflecting continued strong strategy execution [Yahoo! Finance]Yahoo! Finance
EVAX
Analyst Actions
- 11/1/24 - HC Wainwright
EVAX
Sec Filings
- 12/26/24 - Form 6-K
- 12/17/24 - Form F-1/A
- 12/17/24 - Form 6-K
- EVAX's page on the SEC website